162 related articles for article (PubMed ID: 29772250)
21. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF
Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
[TBL] [Abstract][Full Text] [Related]
22. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A.
Yang J; Wang X; Fuh G; Yu L; Wakshull E; Khosraviani M; Day ES; Demeule B; Liu J; Shire SJ; Ferrara N; Yadav S
Mol Pharm; 2014 Oct; 11(10):3421-30. PubMed ID: 25162961
[TBL] [Abstract][Full Text] [Related]
23. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells.
Spitzer MS; Yoeruek E; Sierra A; Wallenfels-Thilo B; Schraermeyer U; Spitzer B; Bartz-Schmidt KU; Szurman P
Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1837-42. PubMed ID: 17347807
[TBL] [Abstract][Full Text] [Related]
24. Antivascular endothelial growth factors in age-related macular degeneration.
Schmidt-Erfurth U; Pollreisz A; Mitsch C; Bolz M
Dev Ophthalmol; 2010; 46():21-38. PubMed ID: 20703030
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies.
Stubenrauch K; Wessels U; Essig U; Vogel R; Schleypen J
J Pharm Biomed Anal; 2010 Jun; 52(2):249-54. PubMed ID: 20083366
[TBL] [Abstract][Full Text] [Related]
26. Detection of aqueous VEGF concentrations before and after intravitreal injection of anti-VEGF antibody using low-volume sampling paper-based ELISA.
Hsu MY; Hung YC; Hwang DK; Lin SC; Lin KH; Wang CY; Choi HY; Wang YP; Cheng CM
Sci Rep; 2016 Oct; 6():34631. PubMed ID: 27725716
[TBL] [Abstract][Full Text] [Related]
27. Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes.
MacDonald DA; Martin J; Muthusamy KK; Luo JK; Pyles E; Rafique A; Huang T; Potocky T; Liu Y; Cao J; Bono F; Delesque N; Savi P; Francis J; Amirkhosravi A; Meyer T; Romano C; Glinka M; Yancopoulos GD; Stahl N; Wiegand SJ; Papadopoulos N
Angiogenesis; 2016 Jul; 19(3):389-406. PubMed ID: 27234973
[TBL] [Abstract][Full Text] [Related]
28. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
Schottler J; Randoll N; Lucius R; Caliebe A; Roider J; Klettner A
Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
[TBL] [Abstract][Full Text] [Related]
29. Comparison of bioanalytical methods for the quantitation of PEGylated human insulin.
de Dios K; Manibusan A; Marsden R; Pinkstaff J
J Immunol Methods; 2013 Oct; 396(1-2):1-7. PubMed ID: 23933323
[TBL] [Abstract][Full Text] [Related]
30. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration.
Wang X; Sawada T; Sawada O; Saishin Y; Liu P; Ohji M
Am J Ophthalmol; 2014 Oct; 158(4):738-744.e1. PubMed ID: 24973606
[TBL] [Abstract][Full Text] [Related]
31. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.
Gaudreault J; Fei D; Rusit J; Suboc P; Shiu V
Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):726-33. PubMed ID: 15671306
[TBL] [Abstract][Full Text] [Related]
32. Endothelial progenitor cells and plasma vascular endothelial growth factor and stromal cell-derived factor-1 during ranibizumab treatment for neovascular age-related macular degeneration.
Grierson R; Meyer-Rüsenberg B; Kunst F; Berna MJ; Richard G; Thill M
J Ocul Pharmacol Ther; 2013; 29(6):530-8. PubMed ID: 23573802
[TBL] [Abstract][Full Text] [Related]
33. Ranibizumab and Bevacizumab but Not Aflibercept Inhibit Proliferation of Primary Human Retinal Pigment Epithelium in vitro.
Parisi L; Fuhrer R; Zinkernagel M; Enzmann V
Ophthalmologica; 2019; 241(3):137-142. PubMed ID: 30001546
[TBL] [Abstract][Full Text] [Related]
34. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
[TBL] [Abstract][Full Text] [Related]
35. Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells.
Merz PR; Röckel N; Ballikaya S; Auffarth GU; Schmack I
BMC Ophthalmol; 2018 Dec; 18(1):316. PubMed ID: 30537942
[TBL] [Abstract][Full Text] [Related]
36. SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER BEVACIZUMAB OR RANIBIZUMAB TREATMENT FOR RETINOPATHY OF PREMATURITY.
Wu WC; Shih CP; Lien R; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
Retina; 2017 Apr; 37(4):694-701. PubMed ID: 27467377
[TBL] [Abstract][Full Text] [Related]
37. The bioanalysis of the monoclonal antibody trastuzumab by high-performance liquid chromatography with fluorescence detection after immuno-affinity purification from human serum.
Damen CW; Derissen EJ; Schellens JH; Rosing H; Beijnen JH
J Pharm Biomed Anal; 2009 Dec; 50(5):861-6. PubMed ID: 19487098
[TBL] [Abstract][Full Text] [Related]
38. Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice.
Jo DH; Park SW; Cho CS; Powner MB; Kim JH; Fruttiger M; Kim JH
PLoS One; 2015; 10(7):e0134308. PubMed ID: 26226015
[TBL] [Abstract][Full Text] [Related]
39. Toxicity testing of the VEGF inhibitors bevacizumab, ranibizumab and pegaptanib in rats both with and without prior retinal ganglion cell damage.
Thaler S; Fiedorowicz M; Choragiewicz TJ; Bolz S; Tura A; Henke-Fahle S; Yoeruek E; Zrenner E; Bartz-Schmidt KU; Ziemssen F; Schuettauf F
Acta Ophthalmol; 2010 Aug; 88(5):e170-6. PubMed ID: 20491691
[TBL] [Abstract][Full Text] [Related]
40. Aqueous vascular endothelial growth factor after intravitreal injection of pegaptanib or ranibizumab in patients with age-related macular degeneration.
Sawada O; Miyake T; Kakinoki M; Sawada T; Kawamura H; Ohji M
Retina; 2010; 30(7):1034-8. PubMed ID: 20616682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
